SynAct Pharma to present at the 2023 BIO International Convention

SynAct Pharma AB (publ) (“SynAct”) today announced that CEO Torbjørn Bjerke will present at the upcoming 2023 BIO International Convention on June 6, 2023, in Boston, Massachusetts. Bjerke will speak to senior biotech executives, business development leaders and investors about SynAct’s lead asset AP1189 and resolution of inflammation through the selective activation of the melanocortin system.

“Being selected to preset at BIO is in part validation of the hard work we have done to advance our once-daily oral AP1189 program in rheumatoid arthritis,” said SynAct Pharma’s CEO Torbjørn Bjerke. “SynAct is at an incredible inflection point with clinical study data from both the EXPAND and RESOLVE RA studies due in the second half of this year. AP1189 and the selective melanocortin receptors that we acquired earlier this year could help usher in a new way to approach chronic inflammatory diseases with resolution therapy, modulating instead of suppressing the immune system.”

The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world’s largest industry gathering and brings together thousands of global biotechnology, and biopharmaceutical leaders. The four-day, in-person event includes networking, programming and partnering opportunities.

The information was submitted, through the agency of the contact person below, for publication on May 31, 2023, at 08:00 CEST.

For further information, please contact:
Torbjørn Bjerke, MD
CEO, SynAct Pharma AB
Phone: +46 727 44 41 58
Mail: TBJE@synactpharma.com
Mail: investor.relations@synactpharma.com

Datum 2023-05-31, kl 08:00
Källa MFN
Ungdomsdeal - 200 kr ! Just nu får alla nya kunder mellan 18 och 25 år 200 kr gratis när man skapar konto på Nordnet, insatt i fonden Nordnet One Balanserad. Bra läge att testa Nordnet!
Investeringar i värdepapper och fonder innebär alltid en risk och det är inte säkert att du får tillbaka det investerade kapitalet